Anzeige
Mehr »
Login
Montag, 06.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Cannabisaktien sollten nun den S&P um 60% outperformen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
36 Leser
Artikel bewerten:
(0)

2012 ISPE Annual Meeting to Reflect Association's New Strategic Plan

TAMPA, Fla., Oct. 11,2012 /PRNewswire-USNewswire/ --The 2012 ISPE Annual Meeting will feature an all-new education program and new enhancements that are reflective of the organization's new strategic plan, which emphasizes interaction and cooperation between pharmaceutical industry leaders and regulatory authorities, increased emphasis on product quality and patient safety and a focus on the entire product lifecycle. The four-day meeting will take place 11 - 14 November in San Francisco, Calif. USA.

(Logo: http://photos.prnewswire.com/prnh/20120912/DC73253LOGO )

"ISPE has made it a priority to expand our overall educational offerings to include more regulatory and strategic discussions as part of our transition to an approach that considers the entire product lifecycle," said ISPE President and CEO Nancy Berg. "This year's Annual Meeting education program reflects that, and as a result, we are seeing record-setting global registrations. This year's meeting will be a brand-new experience for our Members and the industry professionals and regulators who attend."

Among the elevated offerings at this year's Annual Meeting are a plenary session with presentations from the FDA's Dr. Stephen Spielberg and the IMS Institute for Healthcare Informatics' Murray Aitken, an Executive Series and an International Regulatory Summit. Many education sessions, including those in the Executive Series, are expected to fill to capacity in the coming weeks.

The enhanced education program and International Regulatory Summit at the 2012 ISPE Annual Meeting are also drawing a record number of regulators as both speakers and attendees. In addition to Dr. Stephen Spielberg, confirmed regulators from the US FDA to-date include Jeffrey Baker, Ilisa Bernstein, Rick Friedman, Bogdan Kurtyka, Steve Lynn, Christina Moore, Yingxu Ping and Lawrence Yu. Other confirmed regulators include Mark Birse (MHRA), Joyce N. Cirunay (FDA Philippines), Dr. Rodolfo Mocchetto (ANMAT), Song Shufen and Liu Yuan (CCD, SFDA), among others.

ISPE has released a new video to highlight the program enhancements delegates will see at this year's meeting. Additional information, including complete program, speaker, and registration information, is available on the 2012 ISPE Annual Meeting website.

About ISPE
ISPE, the International Society for Pharmaceutical Engineering, is the world's largest not-for-profit association serving its Members through leading scientific, technical and regulatory advancement throughout the entire pharmaceutical lifecycle. The 20,000 Members of ISPE are building solutions in the development and manufacture of safe and effective pharmaceutical and biologic medicines and medical delivery devices in more than 90 countries around the world. Founded in 1980, ISPE has its worldwide headquarters in Tampa, Florida, USA and offices in Brussels, Belgium, Singapore and Shanghai, China. Visit www.ISPE.org for more information.

For more information contact:
Danielle Hould
ISPE Communications Manager
Tel: +1-813-960-2105, ext. 277
email: dhould@ispe.org
www.ISPE.org

SOURCE ISPE

Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!
In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.
Hier klicken
© 2012 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.